Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., Cowey, C. L., . . . Wolchok, J. D. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The lancet oncology, 19(11), 1480-1492. https://doi.org/10.1016/S1470-2045(18)30700-9
Citace podle Chicago (17th ed.)Hodi, Frank Stephen, et al. "Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab Alone in Advanced Melanoma (CheckMate 067): 4-year Outcomes of a Multicentre, Randomised, Phase 3 Trial." The Lancet Oncology 19, no. 11 (2018): 1480-1492. https://doi.org/10.1016/S1470-2045(18)30700-9.
Citace podle MLA (9th ed.)Hodi, Frank Stephen, et al. "Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab Alone in Advanced Melanoma (CheckMate 067): 4-year Outcomes of a Multicentre, Randomised, Phase 3 Trial." The Lancet Oncology, vol. 19, no. 11, 2018, pp. 1480-1492, https://doi.org/10.1016/S1470-2045(18)30700-9.